CA3217565A1 - Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors - Google Patents
Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors Download PDFInfo
- Publication number
- CA3217565A1 CA3217565A1 CA3217565A CA3217565A CA3217565A1 CA 3217565 A1 CA3217565 A1 CA 3217565A1 CA 3217565 A CA3217565 A CA 3217565A CA 3217565 A CA3217565 A CA 3217565A CA 3217565 A1 CA3217565 A1 CA 3217565A1
- Authority
- CA
- Canada
- Prior art keywords
- methyl
- 6alkyl
- chloro
- unsubstituted
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163185637P | 2021-05-07 | 2021-05-07 | |
| US63/185,637 | 2021-05-07 | ||
| US202163286691P | 2021-12-07 | 2021-12-07 | |
| US63/286,691 | 2021-12-07 | ||
| PCT/US2022/027763 WO2022235859A1 (en) | 2021-05-07 | 2022-05-05 | Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3217565A1 true CA3217565A1 (en) | 2022-11-10 |
Family
ID=81927873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3217565A Pending CA3217565A1 (en) | 2021-05-07 | 2022-05-05 | Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20220380338A1 (https=) |
| EP (1) | EP4334293A1 (https=) |
| JP (3) | JP7522943B2 (https=) |
| KR (1) | KR20240005878A (https=) |
| CN (1) | CN117881664A (https=) |
| AR (1) | AR125786A1 (https=) |
| AU (1) | AU2022270115B2 (https=) |
| BR (1) | BR112023023239A2 (https=) |
| CA (1) | CA3217565A1 (https=) |
| CL (1) | CL2023003295A1 (https=) |
| CO (1) | CO2023015096A2 (https=) |
| CR (1) | CR20230519A (https=) |
| DO (1) | DOP2023000242A (https=) |
| EC (1) | ECSP23083881A (https=) |
| GE (2) | GEP20257795B (https=) |
| IL (1) | IL308215A (https=) |
| JO (1) | JOP20230284A1 (https=) |
| MX (1) | MX2023013146A (https=) |
| PE (1) | PE20250021A1 (https=) |
| TW (1) | TWI827037B (https=) |
| WO (1) | WO2022235859A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022270061B2 (en) * | 2021-05-07 | 2026-02-19 | Merck Sharp & Dohme Llc | Aryl 3-oxopiperazine carboxamides and heteroaryl 3-oxopiperazine carboxamides as nav1.8 inhibitors |
| CA3257285A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | HETEROARYL COMPOUNDS FOR PAIN RELIEF |
| CA3256248A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | HETEROARYL COMPOUNDS FOR PAIN RELIEF |
| US20230382910A1 (en) | 2022-04-22 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2023205463A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2024123815A1 (en) | 2022-12-06 | 2024-06-13 | Vertex Pharmaceuticals Incorporated | Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels |
| WO2025085564A1 (en) * | 2023-10-16 | 2025-04-24 | Kronos Bio, Inc. | Lysine acetyltransferase inhibitors |
| CN117645533B (zh) * | 2023-10-20 | 2024-10-11 | 泰州精英化成医药科技有限公司 | 一种4-(三氟甲基)环己酮的合成方法 |
| WO2025090516A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing compounds for treating pain and solid forms thereof |
| WO2025090511A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing modulators of sodium channels and solid forms of the same for treating pain |
| WO2025090480A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2025090465A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| CN117567323A (zh) * | 2023-10-30 | 2024-02-20 | 湖北泰盛化工有限公司 | 一种(s)-4-氯-2-((甲氧基羰基)氨基)丁酸乙酯的制备方法 |
| US20250186419A1 (en) | 2023-12-07 | 2025-06-12 | Vertex Pharmaceuticals Incorporated | Dosing regimens for treating pain |
| US20260001877A1 (en) | 2024-06-28 | 2026-01-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2026013449A2 (en) | 2024-07-11 | 2026-01-15 | Sea4Us - Biotecnologia E Recursos Marinhos, Sa | Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain |
| WO2026030525A1 (en) | 2024-07-31 | 2026-02-05 | Vertex Pharmaceuticals Incorporated | Zilvetrigine dosage forms and dosing regimens for treating pain |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS52122392A (en) * | 1976-04-07 | 1977-10-14 | Sangyo Kagaku Kenkyu Kyokai | Novel antibacterials |
| WO2005061470A1 (en) * | 2003-12-18 | 2005-07-07 | Cv Therapeutics, Inc. | 1-akan-2-ol substituted piperazine and piperidine compounds |
| KR20100075631A (ko) | 2007-10-11 | 2010-07-02 | 버텍스 파마슈티칼스 인코포레이티드 | 전압개폐 나트륨 채널의 억제제로서 유용한 아릴 아미드 |
| WO2009049181A1 (en) | 2007-10-11 | 2009-04-16 | Vertex Pharmaceuticals Incorporated | Amides useful as inhibitors of voltage-gated sodium channels |
| AU2008310660A1 (en) | 2007-10-11 | 2009-04-16 | Vertex Pharmaceuticals Incorporated | Heteroaryl amides useful as inhibitors of voltage-gated sodium channels |
| WO2011026240A1 (en) * | 2009-09-04 | 2011-03-10 | Zalicus Pharmaceuticals Ltd. | Oxopiperazine derivatives for the treatment of pain and epilepsy |
| US8889863B2 (en) * | 2010-07-16 | 2014-11-18 | Vanderbilt University | Stereoselective methods, catalysts and intermediates for the synthesis of (−)-Nutlin-3 and related compounds |
| RS56015B1 (sr) | 2013-01-31 | 2017-09-29 | Vertex Pharma | Piridon amidi kao modulatori natrijumovih kanala |
| CA2898653C (en) | 2013-01-31 | 2021-09-28 | Vertex Pharmaceuticals Incorporated | Amides as modulators of sodium channels |
| RU2683788C2 (ru) | 2013-01-31 | 2019-04-02 | Вертекс Фармасьютикалз Инкорпорейтед | Амиды хинолина и хиназолина, полезные в качестве модуляторов натриевых каналов |
| UA119147C2 (uk) | 2013-07-19 | 2019-05-10 | Вертекс Фармасьютікалз Інкорпорейтед | Сульфонаміди як модулятори натрієвих каналів |
| CA2931550C (en) | 2013-12-13 | 2023-09-26 | Vertex Pharmaceuticals Incorporated | Prodrugs of pyridone amides useful as modulators of sodium channels |
| JP2017114764A (ja) * | 2014-04-25 | 2017-06-29 | 武田薬品工業株式会社 | 片頭痛治療剤 |
| WO2015184383A1 (en) * | 2014-05-29 | 2015-12-03 | St. Jude Children's Research Hospital | Aryl-substituted imidazoles and methods of making and using same |
| WO2017209322A1 (ko) | 2016-05-31 | 2017-12-07 | 한림대학교 산학협력단 | 5원 헤테로사이클릭 유도체, 이의 제조방법 및 이를 포함하는 약제학적 조성물 |
| EP3625214B1 (en) | 2017-05-16 | 2022-07-06 | Vertex Pharmaceuticals Incorporated | Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels |
| AU2018300150A1 (en) | 2017-07-11 | 2020-01-30 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| AU2018371216B2 (en) * | 2017-11-23 | 2024-09-19 | Oslo University Hospital Hf | Treatment of tachycardia |
| EP3802551A4 (en) * | 2018-05-25 | 2022-03-02 | Venatorx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
| JP7288051B2 (ja) | 2018-11-02 | 2023-06-06 | メルク・シャープ・アンド・ドーム・エルエルシー | Ｎａｖ１．８阻害薬としての２－アミノ－Ｎ－ヘテロアリール－ニコチンアミド類 |
| US12344595B2 (en) * | 2018-11-02 | 2025-07-01 | Merck Sharp & Dohme Llc | 2-amino-n-phenyl-nicotinamides as NAV1.8 inhibitors |
| US20230114728A1 (en) * | 2019-11-26 | 2023-04-13 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
| US11802122B2 (en) * | 2020-06-17 | 2023-10-31 | Merck Sharp & Dohme Llc | 2-oxoimidazolidine-4-carboxamides as NAv1.8 inhibitors |
| CN115697327A (zh) * | 2020-06-17 | 2023-02-03 | 默沙东有限责任公司 | 作为nav1.8抑制剂的5-氧代-吡咯烷-3-甲酰胺 |
-
2022
- 2022-05-05 GE GEAP202216407A patent/GEP20257795B/en unknown
- 2022-05-05 IL IL308215A patent/IL308215A/en unknown
- 2022-05-05 JP JP2023567928A patent/JP7522943B2/ja active Active
- 2022-05-05 US US17/737,070 patent/US20220380338A1/en active Pending
- 2022-05-05 PE PE2023003016A patent/PE20250021A1/es unknown
- 2022-05-05 WO PCT/US2022/027763 patent/WO2022235859A1/en not_active Ceased
- 2022-05-05 AU AU2022270115A patent/AU2022270115B2/en active Active
- 2022-05-05 GE GEAP202416407A patent/GEAP202416407A/en unknown
- 2022-05-05 BR BR112023023239A patent/BR112023023239A2/pt unknown
- 2022-05-05 EP EP22727539.3A patent/EP4334293A1/en active Pending
- 2022-05-05 TW TW111116959A patent/TWI827037B/zh active
- 2022-05-05 AR ARP220101186A patent/AR125786A1/es unknown
- 2022-05-05 CR CR20230519A patent/CR20230519A/es unknown
- 2022-05-05 KR KR1020237042098A patent/KR20240005878A/ko active Pending
- 2022-05-05 CA CA3217565A patent/CA3217565A1/en active Pending
- 2022-05-05 MX MX2023013146A patent/MX2023013146A/es unknown
- 2022-05-05 CN CN202280048071.1A patent/CN117881664A/zh active Pending
-
2023
- 2023-11-01 DO DO2023000242A patent/DOP2023000242A/es unknown
- 2023-11-06 EC ECSENADI202383881A patent/ECSP23083881A/es unknown
- 2023-11-06 JO JOJO/P/2023/0284A patent/JOP20230284A1/ar unknown
- 2023-11-06 CL CL2023003295A patent/CL2023003295A1/es unknown
- 2023-11-07 CO CONC2023/0015096A patent/CO2023015096A2/es unknown
-
2024
- 2024-01-05 JP JP2024000646A patent/JP2024038267A/ja active Pending
-
2025
- 2025-12-18 JP JP2025264265A patent/JP2026048891A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| GEAP202416407A (en) | 2024-03-25 |
| JP2024515895A (ja) | 2024-04-10 |
| CO2023015096A2 (es) | 2023-11-20 |
| ECSP23083881A (es) | 2023-12-29 |
| MX2023013146A (es) | 2023-11-28 |
| EP4334293A1 (en) | 2024-03-13 |
| TWI827037B (zh) | 2023-12-21 |
| CR20230519A (es) | 2024-01-19 |
| US20220380338A1 (en) | 2022-12-01 |
| DOP2023000242A (es) | 2023-12-15 |
| BR112023023239A2 (pt) | 2024-01-23 |
| PE20250021A1 (es) | 2025-01-07 |
| GEP20257795B (en) | 2025-09-25 |
| CN117881664A (zh) | 2024-04-12 |
| JP7522943B2 (ja) | 2024-07-25 |
| JOP20230284A1 (ar) | 2023-11-06 |
| AU2022270115B2 (en) | 2025-08-07 |
| CL2023003295A1 (es) | 2024-07-12 |
| JP2024038267A (ja) | 2024-03-19 |
| TW202308999A (zh) | 2023-03-01 |
| AU2022270115A1 (en) | 2023-11-16 |
| JP2026048891A (ja) | 2026-03-17 |
| KR20240005878A (ko) | 2024-01-12 |
| WO2022235859A1 (en) | 2022-11-10 |
| AR125786A1 (es) | 2023-08-16 |
| IL308215A (en) | 2024-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3217565A1 (en) | Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors | |
| AU2022270061B2 (en) | Aryl 3-oxopiperazine carboxamides and heteroaryl 3-oxopiperazine carboxamides as nav1.8 inhibitors | |
| CA3180372A1 (en) | 5-oxopyrrolidine-3-carboxamides as nav1.8 inhibitors | |
| JP7575518B2 (ja) | Ｎａｖ１．８阻害剤としての２－オキソイミダゾリジン－４－カルボキサミド | |
| US12516046B2 (en) | 2-oxo-oxazolidine-5-carboxamides as NAV1.8 inhibitors | |
| JP2024517678A (ja) | ソルチリン活性の修飾物質 | |
| AU2017233716B2 (en) | Dopamine D3 receptor selective antagonists/partial agonists; method of making; and use thereof | |
| TW201821404A (zh) | 作為ROR γ調節劑之三環碸 | |
| CA3182610C (en) | 2-oxo-oxazolidine-5-carboxamides as nav1.8 inhibitors | |
| EA051500B1 (ru) | ЦИКЛОАЛКИЛ 3-ОКСОПИПЕРАЗИНКАРБОКСАМИДЫ И ЦИКЛОГЕТЕРОАЛКИЛ 3-ОКСОПИПЕРАЗИНКАРБОКСАМИДЫ В КАЧЕСТВЕ ИНГИБИТОРОВ NaV1.8 | |
| HK40108385A (zh) | 作为nav1.8抑制剂的环烷基3-氧代哌嗪甲酰胺和环杂烷基3-氧代哌嗪甲酰胺 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20241016 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241104 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250325 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250325 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250409 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250409 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260409 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260409 |